Per-Ola Andersson

7PUBLICATIONS
24CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical virologyHaematological tumoursSocial epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 05, 2026
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

|Apr 23, 2025
Temporal trends in relative survival of diffuse large B-cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies.

Sara Harrysson, Sandra Eloranta, Stefanie Antonilli

|Mar 31, 2025
Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation.

Sofie Johansson Alm, Gustav Orrsjö, Giti Shah Barkhordar

|Apr 25, 2022
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.

Sara Harrysson, Sandra Eloranta, Sara Ekberg

|May 05, 2021
Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study.

Amal Abu Sabaa, Charlott Mörth, Sverker Hasselblom

|May 18, 2018
Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma.

Sara Ekberg, Mats Jerkeman, Per-Ola Andersson

Pageof 2

Frequent Collaborators

3 joint publications

Sandra Eloranta

2 joint publications

Sara Ekberg

2 joint publications

Sara Harrysson

2 joint publications

Kristina Sonnevi